Description: Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Home Page: www.mirati.com
3545 Cray Court
San Diego,
CA
92121
United States
Phone:
858 332 3410
Officers
| Name | Title |
|---|---|
| Mr. David D. Meek | CEO & Director |
| Dr. Charles M. Baum M.D., Ph.D. | Founder, Pres, Head of R&D and Director |
| Dr. James G. Christensen Ph.D. | Exec. VP & Chief Scientific Officer |
| Mr. Benjamin J. Hickey M.B.A. | Chief Commercial Officer |
| Ms. Laurie D. Stelzer | Chief Financial Officer |
| Ms. Reena R. Desai | Chief Legal Officer & Corp. Sec. |
| Mr. Michael E. Paolucci | Chief People Officer |
| Dr. Kelly Covello Ph.D. | VP & Head of Medical Affairs |
| Mr. Ryan Asay | VP & Head of Corp. Affairs |
| Dr. Alan Bart Sandler M.D. | Exec. VP & Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1181 |
| Price-to-Sales TTM: | 201.8412 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 413 |